Harrow Health (NASDAQ:HROW) Maintains "Outperform" Rating: A Closer Look

Core Viewpoint - Harrow Health (HROW) has garnered investor interest, with a recent "Outperform" rating from William Blair, despite a notable decline in stock price [1][3]. Financial Performance - The Q4 2025 earnings call provided insights into Harrow's financial performance, highlighting achievements and challenges, as well as future outlook [2]. - Harrow Health's market capitalization is approximately $1.43 billion, indicating its size and market presence [4]. Stock Performance - HROW has seen a significant decrease of about 28%, with a drop of $14.99, and the stock price fluctuated between $38.56 and $44.68 during the day [3]. - Over the past year, the stock reached a high of $54.85 and a low of $20.85, reflecting volatility [3]. - The trading volume of 3,933,928 shares indicates active investor interest, which is important for understanding liquidity and growth potential [4].